Novartis Ag

Morphosys Ag

Novartis Pharma Ag

Tet Systems Gmbh & Co., Kg

Stefanie Urlinger

Julia Neugebauer

Christoph Heusser

Eveline Schaadt

Thomas Tiller

Maximilian Woisetschlaeger

Josef Prassler

Markus Enzelberger

Tanja Herrmann

Yvonne Stark

Ingrid Schuster

Marta Cosenza

Michael Otto Bardroff

Seth Alexander Ettenberg

Mark C Fishman

Feng Cong

Janine R Shulok

Mariel Donzeau

Hermann Bujard

Christine Rothe

Estelle Trifilieff

Steffen Runz

Stefanie Thiel

Catrin Berger

Kelly-Ann Sheppard

Chris Lu

Wolfgang Hillen

Seth Ettenberg

Janine Shulok

Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Anti-BAFFR antibody formulations and methods of use thereof

The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region. The modified constant region prevents the recognition of the Fab molecules by anti-Fab antibodies present in a host's serum. The disclosure further relates to methods of generating such modified Fab molecules for biological, diagnostic, pharmaceutical and other uses.

Fab molecules with a rodent hinge region and a non-rodent CH1 region

The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.

Collection and methods for its use

The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display.

Anti-BAFFR antibody formulations

The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.

Compositions and methods of use for therapeutic antibodies

Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.

Compositions and methods of use for antibodies of Dickkopf-1

Compositions and methods of use for antibodies of dickkopf-1

This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Compositions and methods for increasing muscle growth

The present invention is directed to the preparation and use of a collection of antibody heavy chain complementarity determining region 3 (HCDR) members, where diversity of the collection is a function of the length of the HCDRmembers. The diversity of the collection of HCDRregions substantially represents the natural amino acid distribution of HCDRin the human repertoire. This natural amino acid distribution can be represented by biasing the complete random distribution of amino acids, accordingly, in the HCDRencoding DNA sequence by using trinucleotide mutagenesis (TRIM) technology. A collection of HCDRmembers of the invention each can be comprised within a variable region of an antibody (or fragment thereof) to form a library of synthetic antibodies or antibody fragments. The invention also provides nucleic acid molecules encoding such diverse collection and methods of making and using the same.

Collection of HCDR3 regions and uses therefor

Growing community of inventors

Munich, Germany

Stefanie Urlinger